Cemiplimab time-varying population PK
A two-compartment population PK model representing cemiplimab exposure, covariate-dependent disposition, and gradual time variation in clearance.
- Therapeutic
- Cemiplimab, Libtayo, REGN2810, cemiplimab-rwlc
- Target
- PD-1 / PDCD1
- Disease
- Advanced malignancies
Biological model
A two-compartment population PK model representing cemiplimab exposure, covariate-dependent disposition, and gradual time variation in clearance.
Intervention
Cemiplimab, Libtayo, REGN2810, cemiplimab-rwlc
Biological focus
PD-1 / PDCD1
Context
Advanced malignancies
Model details
A two-compartment population PK model representing cemiplimab exposure, covariate-dependent disposition, and gradual time variation in clearance.
Modeled states
- AUC day mg Lday*mg/L
Modeled dynamic state for auc day mg l.
- A central mgmg
Modeled dynamic state for a central mg.
- A peripheral mgmg
Modeled dynamic state for a peripheral mg.
- elapsed time dayday
Modeled dynamic state for elapsed time day.
Key readouts
- Central cemiplimab concentrationunknown
Model-derived readout for central cemiplimab concentration.
- Cumulative cemiplimab exposureday*mg/L
Model-derived readout for cumulative cemiplimab exposure.
- Individual clearanceunknown
Model-derived readout for individual clearance.
- Time-varying clearance factorunknown
Model-derived readout for time-varying clearance factor.
- A central mgmg
Model-derived readout for a central mg.
Explore this model
Choose a starting point to view its result. Adjust key model inputs when you want to explore a different outcome.
Typical 3 mg/kg every 2 weeks IV regimen
How do dosing, patient covariates, and time-varying clearance shape cemiplimab exposure? Explore this intervention regimen through Central cemiplimab concentration, Cumulative cemiplimab exposure, Individual clearance, Time-varying clearance factor. This is a mechanistic product exploration, not a paper-result reproduction.
Questions to explore
- How do dosing, patient covariates, and time-varying clearance shape cemiplimab exposure?
Starting result
This result reflects the starting settings. Run your changes to update it.
Model inputs
Five scientist-facing controls at most.
Compare a parameter
How does one model input change the response?
How do dosing, patient covariates, and time-varying clearance shape cemiplimab exposure?
TVCL L day
Model parameter controlling tvcl l day.
Exploratory range around the default value.
5 evenly spaced values in L/day. Other model inputs and the simulation window stay fixed.
Interpret with care
- Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.
- Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario.
Review the server-confirmed fixed price before starting the comparison.
Comparative response
End-of-window response across the selected parameter values.
Choose an exploratory range around the default, review the fixed price, and run the comparison.
Scientific reference
Supporting publication
Population pharmacokinetic characteristics of cemiplimab in patients with advanced malignanciesJournal of Pharmacokinetics and Pharmacodynamics
